For healthcare professionals only
This promotional website has been developed, organised and funded by Boehringer Ingelheim.
Prescribing information for Great Britain and Northern Ireland and the Republic of Ireland.
Adverse event reporting information can be found at the bottom of the page.
Proven efficacy vs placebo1,7
Proven efficacy vs placebo1,7: The efficacy and safety of 5 mg linagliptin was evaluated in eight phase III randomised controlled trials. Linagliptin once daily demonstrated clinically significant improvements in glycaemic control vs placebo or comparator.1
Demonstrated CV and kidney safety profile
Long-term cardiovascular and kidney safety profile of TRAJENTA® has been demonstrated in two cardiovascular outcome trials.8-14 As TRAJENTA® is primarily excreted via the bile, it is suitable for a broad range of adults with type 2 diabetes independent of renal function.1
Unique convenience of one dose, once daily1
The recommended dose of TRAJENTA® for adult patients with type 2 diabetes is 5 mg once daily, independent of renal and hepatic function, body mass index, age, ethnicity, background type 2 diabetes therapy, and disease duration.1,14
The event starts in:
Coming soon
Join our faculty as they discuss the role of clinical inertia in the suboptimal achievement of treatment targets and share practical tips for addressing this topic with your adult type 2 diabetes patients
*Summary of Product Characteristics for Trajenta, sitagliptin, vildagliptin and saxagliptin are available at: https://www.medicines.org.uk (GB), https://www.emcmedicines.com/en-GB/northernireland/ (NI) and https://www.medicines.ie/ (ROI).
**Summary of Product Characteristics for alogliptin are available at: https://www.medicines.org.uk (GB) and https://www.emcmedicines.com/en-GB/northernireland/ (NI).
Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
• monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control
The content has been reviewed and approved by the sponsoring company prior to its publication. Editorial support for this website has been provided by
OmniaMed Communications.
PC-GB-106627 V6 | December 2023
The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions. Copyright 2023 Oxbridge Solutions Ltd®. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions Ltd® receives funding from advertising but maintains editorial independence. GPnotebook stores small data files on your computer called cookies so that we can recognise you and provide you with the best service. If you do not want to receive cookies please do not use GPnotebook.
